Codagenix Inc.

Codagenix Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells. The highly attenuated viruses make excellent vaccines or oncolytics against solid tumors. Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses.

Company Details

Employees
22
Founded
-
Address
3 Bioscience Park Dr, Farmingdale,new York 11735,united States
Phone
5168290353
Email
in****@****nix.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Farmingdale, New York
Looking for a particular Codagenix Inc. employee's phone or email?

Codagenix Inc. Questions

News

Everything you need to know about next-generation coronavirus vaccines - Gavi, the Vaccine Alliance

Everything you need to know about next-generation coronavirus vaccines Gavi, the Vaccine Alliance

Codagenix announces late-breaking presentation of positive clinical immunogenicity data for COVID-19 vaccine candidate CoviLiv™ at IDWeek 2023 - European AIDS Treatment Group

Codagenix announces late-breaking presentation of positive clinical immunogenicity data for COVID-19 vaccine candidate CoviLiv™ at IDWeek 2023 European AIDS Treatment Group

Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine Target with Global Public Health Demand - PR Newswire

Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine Target with Global Public Health Demand PR Newswire

Codagenix announces promising findings for intranasal COVID vaccine - CIDRAP

Codagenix announces promising findings for intranasal COVID vaccine CIDRAP

Codagenix in Vaccine Tech Licensing Deal with Stony Brook - Stony Brook University

Codagenix in Vaccine Tech Licensing Deal with Stony Brook Stony Brook University

Codagenix Appoints Lori Rudolph-Owen and Jill Howe to Board - citybiz

Codagenix Appoints Lori Rudolph-Owen and Jill Howe to Board citybiz

Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy - PNAS

Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy PNAS

Codagenix initiates new study of live-attenuated vaccine in RSV - Clinical Trials Arena

Codagenix initiates new study of live-attenuated vaccine in RSV Clinical Trials Arena

Codagenix uses synthetic biology and ML in vaccine development - drugdiscoverytrends.com

Codagenix uses synthetic biology and ML in vaccine development drugdiscoverytrends.com

JPM2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development - BioSpace

JPM2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development BioSpace

Inhaling away the virus: Is the next generation of COVID vaccines on its way? - ABC News - Breaking News, Latest News and Videos

Inhaling away the virus: Is the next generation of COVID vaccines on its way? ABC News - Breaking News, Latest News and Videos

Codagenix attracts DOD funding for synthetic biology approach to dengue vaccine - Chemical & Engineering News

Codagenix attracts DOD funding for synthetic biology approach to dengue vaccine Chemical & Engineering News

Why mucosal vaccines could be vital to getting ahead of SARS-CoV-2 - The Pharmaceutical Journal

Why mucosal vaccines could be vital to getting ahead of SARS-CoV-2 The Pharmaceutical Journal

Codagenix Announces BARDA Contract for Project NextGen Supporting Development of CoviLiv™ as an Intranasal COVID-19 Vaccine - PR Newswire

Codagenix Announces BARDA Contract for Project NextGen Supporting Development of CoviLiv™ as an Intranasal COVID-19 Vaccine PR Newswire

What next-gen Covid-19 vaccines might look like - Gavi, the Vaccine Alliance

What next-gen Covid-19 vaccines might look like Gavi, the Vaccine Alliance

Codagenix concludes subject dosing in Phase I influenza vaccine trial - Clinical Trials Arena

Codagenix concludes subject dosing in Phase I influenza vaccine trial Clinical Trials Arena

Licensing Agreement with Codagenix Advances Next Generation Viral Vaccines - SBU News

Licensing Agreement with Codagenix Advances Next Generation Viral Vaccines SBU News

Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies - PR Newswire

Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies PR Newswire

Codagenix Welcomes Bruce Taillon as Executive Vice President of Animal Health - PR Newswire

Codagenix Welcomes Bruce Taillon as Executive Vice President of Animal Health PR Newswire

Cutting-Edge Technology Will Help Fight Viral Infections in Humans and Animals - SBU News

Cutting-Edge Technology Will Help Fight Viral Infections in Humans and Animals SBU News

Codagenix starts human study of COVID-19 vaccine; further Sputnik data unveiled - BioWorld MedTech

Codagenix starts human study of COVID-19 vaccine; further Sputnik data unveiled BioWorld MedTech

A look at what is in the pipeline for RSV vaccines for children - Contemporary Pediatrics

A look at what is in the pipeline for RSV vaccines for children Contemporary Pediatrics

Codagenix raises $20 million for a new flu vaccine and other therapies - TechCrunch

Codagenix raises $20 million for a new flu vaccine and other therapies TechCrunch

ImmunityBio, Codagenix and EuMentis raise funds, while a biotech SPAC dissolves - Endpoints News

ImmunityBio, Codagenix and EuMentis raise funds, while a biotech SPAC dissolves Endpoints News

Codagenix Appoints Johanna Kaufmann EVP - citybiz

Codagenix Appoints Johanna Kaufmann EVP citybiz

Hedge fund billionaire Jim Simons is betting millions on a small biotech firm and its potential coronavirus vaccine - markets.businessinsider.com

Hedge fund billionaire Jim Simons is betting millions on a small biotech firm and its potential coronavirus vaccine markets.businessinsider.com

Codagenix: A Tiny Start-Up Ready To Take On The Goliaths Of The Vaccine Industry - Life Science Leader

Codagenix: A Tiny Start-Up Ready To Take On The Goliaths Of The Vaccine Industry Life Science Leader

Top Companies in Pharm Country Ranked by Revenue - BioSpace

Top Companies in Pharm Country Ranked by Revenue BioSpace

Serum Institute, Codagenix develop vaccine candidate for coronavirus - Business Standard

Serum Institute, Codagenix develop vaccine candidate for coronavirus Business Standard

Top Codagenix Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant